Gary E Raskob
Overview
Explore the profile of Gary E Raskob including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
8431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lanting V, van Bergen En Henegouwen K, Bosch F, Grosso M, Segers A, Raskob G, et al.
J Thromb Haemost
. 2025 Mar;
PMID: 40049418
Background: The management of recurrent venous thromboembolism (VTE) despite anticoagulant treatment in patients with cancer is uncertain. To address this, we used data from the Hokusai VTE Cancer trial, which...
2.
Lanting V, Takada T, Bosch F, Marshall A, Grosso M, Young A, et al.
Thromb Haemost
. 2024 Sep;
PMID: 39299270
Background: About 7% of patients with cancer-associated venous thromboembolism (CAT) develop a recurrence during anticoagulant treatment. Identification of high-risk patients may help guide treatment decisions. Aim: To identify clinical predictors...
3.
Raskob G
NEJM Evid
. 2024 Feb;
2(7):EVIDe2300106.
PMID: 38320170
Direct oral anticoagulants such as apixaban or dabigatran have revolutionized anticoagulant treatment. These drugs, which specifically inhibit either factor Xa or thrombin, respectively, are at least as effective as vitamin...
4.
Wang T, Khorana A, Agnelli G, Bloomfield D, Bonaca M, Buller H, et al.
Oncologist
. 2023 May;
28(7):555-564.
PMID: 37171998
Cancer-associated thrombosis, with the incidence rising over the years, is associated with significant morbidity and mortality in patients with cancer. Recent advances in the treatment of cancer-associated venous thromboembolism (VTE)...
5.
de Winter M, Uijl A, Buller H, Carrier M, Cohen A, Hansen J, et al.
J Thromb Haemost
. 2023 Jan;
21(3):573-585.
PMID: 36696208
Background: Patients with venous thromboembolism (VTE) are commonly classified by the presence or absence of provoking factors at the time of VTE to guide treatment decisions. This approach may not...
6.
de Winter M, Buller H, Carrier M, Cohen A, Hansen J, Kaasjager K, et al.
Eur Heart J
. 2023 Jan;
44(14):1231-1244.
PMID: 36648242
Aims: Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to...
7.
Spyropoulos A, Raskob G, Spiro T, Lu W, De Sanctis Y, Albanese J, et al.
TH Open
. 2022 Oct;
6(4):e304-e308.
PMID: 36299620
This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for...
8.
Raskob G, Ageno W, Albers G, Elliott C, Halperin J, Maynard G, et al.
J Am Heart Assoc
. 2022 Oct;
11(20):e026229.
PMID: 36205248
Background Venous thromboembolism (VTE) often occurs after hospitalization in medically ill patients, but the population benefit-risk of extended thromboprophylaxis remains uncertain. Methods and Results The MARINER (Medically Ill Patient Assessment...
9.
Spyropoulos A, Goldin M, Ageno W, Albers G, Elliott C, Hiatt W, et al.
TH Open
. 2022 Sep;
6(3):e177-e183.
PMID: 36046208
The MARINER trial evaluated whether postdischarge thromboprophylaxis with rivaroxaban could reduce the primary outcome of symptomatic venous thromboembolism (VTE) or VTE-related death in acutely ill medical patients at risk for...
10.
Raskob G, Wendelboe A, Campbell J, Ford L, Ding K, Bratzler D, et al.
J Thromb Haemost
. 2022 Jul;
20(10):2366-2378.
PMID: 35830203
Background: Data on the population-based incidence of cancer-associated venous thromboembolism (VTE) from racially diverse populations are limited. Objective: To evaluate the incidence and burden of cancer-associated VTE, including demographic and...